Completed
PHASE2
INTERVENTIONAL
NCT04867785
A Study of LY3437943 in Participants With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC
Name:
Dulaglutide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change From Baseline in Hemoglobin A1c (HbA1c)
TimeFrame:
Baseline, 24 Weeks
Description:
Change in HbA1c (%) from baseline in LY3437943 relative to placebo. HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
Trial Information
NCT ID
NCT04867785
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025